TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33079199
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with 1 in 10,000 major adverse effects
Study: 33079199
Drug: Vaccine from
Normalized name: Human rabies vaccine from Chicken fibroblast culture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine from non-US country (China)
Study: 33079199
Drug: Vaccine from
Normalized name: Human rabies vaccine from Chicken fibroblast culture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine from non-US country (UK)
Study: 33079199
Drug: Vaccine from
Normalized name: Human rabies vaccine from Chicken fibroblast culture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine from China
Study: 32019154
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (95 µg/day folate from vegetables)
Study: 32019154
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (191 µg/day folate from vegetables)
Study: 34902368
Drug: RT concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT concurrent with temozolomide (TMZ) (75 mg/m2/d, 7 d/week) followed by adjuvant TMZ (CRT group)
Study: 34902368
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) alone (RT group, n = 18; 60 Gy in 30 daily fractions)
Study: 34902368
Drug: RT concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT concurrent with temozolomide (TMZ) (CRT group)
Study: 34447389
Drug: Correlation analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation analysis of antibody titres and carriage density for both pathogens.
Study: 33094725
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (4 L/min)
Study: 38619178
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo gel
Study: 34558823
Drug: Lead-in TDF
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead-in TDF monotherapy
Study: 34558823
Drug: TDF monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF monotherapy followed by NAP + pegIFN
Study: 34558823
Drug: End of
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End of therapy
Study: 34558823
Drug: End of
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End of therapy in 5 participants
Study: 32331071
Drug: SEP-363856 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-363856 (50 or 75 mg/d)
Study: 34836278
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum PS128 (PS128) treatment (LT) - 2 capsules (3 × 10^10 CFU/capsule) each morning and evening for 4 weeks
Study: 34836278
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (PT) - 2 capsules for 4 weeks
Study: 34836278
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum PS128 (PS128) treatment (LT)
Study: 34836278
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (PT)
Study: 36219046
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream 1% QD for 21 days
Study: 32003872
Drug: Long implants
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long implants (10 mm)
Study: 32003872
Drug: Crown-to-implant ratio
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crown-to-implant ratio
Study: 34262113
Drug: Cold atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold atmospheric plasma treatment
Study: 33298342
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment regimens modified to reduce toxicity in older/senior patients; specific dosage and duration not mentioned.
Study: 33298342
Drug: Geriatric assessments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatric assessments to select older patients for rigorous treatment regimens; specific assessment methods not mentioned.
Study: 32701199
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg once daily (3 weeks on, 1 week off)
Study: 35935309
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution 10 mL (Control)
Study: 33909358
Drug: Rehabilitation robot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation robot rehabilitation training synchronizing acupuncture exercise therapy
Study: 33909358
Drug: Acupuncture exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture exercise therapy (Control)
Study: 36007871
Drug: Late evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Late evening snack and oral amino acid capsules (LES and OAA)
Study: 32011196
Drug: A-PRP injections
Normalized name: PRPP
DrugBank: 5-O-phosphono-alpha-D-ribofuranosyl diphosphate (DB01632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-PRP injections
Study: 32011196
Drug: AA-PRP injections
Normalized name: HEMOPHILUS B PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA-PRP injections
Study: 34882161
Drug: Healthy dietary
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy dietary pattern (HDP) with 15 g day-1 wolfberries
Study: 34825898
Drug: Dronabinol (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (5-15 mg/day)
Study: 32068255
Drug: Original bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Original bortezomib dosing regimen
Study: 32068255
Drug: Less frequent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less frequent bortezomib dosing
Study: 36426618
Drug: Automated VR
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated VR cognitive behavior therapy (VR‐CBT) app treatment (n = 77)
Study: 34016257
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy for VT ≥200 beats/min or VF
Study: 34016257
Drug: Appropriate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate therapy for VT <200 beats/min or inappropriate therapy
Study: 34016257
Drug: Combined assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined assessment of all therapy and arrhythmia types
Study: 33120301
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg kg−1 IV
Study: 33120301
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg kg−1 IV and Magnesium 2 g IV
Study: 36380280
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of OK lens and 0.01% atropine eye drops
Study: 36380280
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of OK lens and placebo
Study: 33410736
Drug: Z-drugs
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z-drugs
Study: 33410736
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no Z-drugs)
Study: 34410749
Drug: Tailored Metacognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored Metacognitive Reflection and Insight Therapy (MERIT)
Study: 34410749
Drug: Standard Metacognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Metacognitive Reflection and Insight Therapy (MERIT)
Study: 34841124
Drug: Postponed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postponed treatment of PFPT (Control)
Study: 32436173
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + HA gel (Group 2)
Study: 32436173
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + HA mouth rinse + HA gingival gel (Group 4)
Study: 35168289
Drug: Fibrin spray
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin spray alone
Study: 35060116
Drug: Daily aroma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily aroma (sweet orange essential oil)
Study: 37185596
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg OTO-104
Study: 32169321
Drug: Eyelid warming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyelid warming mask (EWM) applied for 30 min before bedtime daily for 4 weeks
Study: 32169321
Drug: Artificial tears
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tears administered as a single-use every day as needed for 4 weeks
Study: 32169321
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group maintained normal lifestyle without treatment
Study: 35986390
Drug: FX06 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FX06 (2 × 200 mg per day) administered intravenously for 5 consecutive days
Study: 35986390
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously for 5 consecutive days
Study: 36087611
Drug: Vilobelimab (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilobelimab (800 mg intravenously for a maximum of six doses on days 1, 2, 4, 8, 15, and 22)
Study: 33215600
Drug: Adjuvant anthracycline-taxane-based
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant anthracycline-taxane-based chemotherapy followed by endocrine therapy
Study: 36299885
Drug: DEX 200
Normalized name: Videx 200mg Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 200 μg combined with sufentanil 150 μg for PCA
Study: 36299885
Drug: DEX 400
Normalized name: Bidex 400mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 400 μg combined with sufentanil 150 μg for PCA
Study: 36299885
Drug: DEX 0
Normalized name: Peridex 0.12% Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 0 μg combined with sufentanil 150 μg for PCA
Study: 34556563
Drug: Blended learning
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended learning (individual preparation with a course handbook and videoclips, plus a single face-to-face session)
Study: 34331752
Drug: Auricular acupressure
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupressure therapy at the Shen Men point and endocrine point bilaterally
Study: 32172521
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate gel 0.38%
Study: 34617303
Drug: Behavioural activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural activation (BA) + Antidepressant (AD)
Study: 34617303
Drug: Trial-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial-based cognitive therapy (TBCT) + Antidepressant (AD)
Study: 35703373
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clobetasol 0.05% lotion and oral NAC
Study: 35703373
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clobetasol 0.05% lotion and oral PTX
Study: 35703373
Drug: Clobetasol 0.05%
Normalized name: CLOBETASOL 0.05% EMOLLIENT TOP CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol 0.05% lotion
Study: 35358097
Drug: Incisional negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional negative pressure wound therapy
Study: 33120891
Drug: Whole-body cryotherapy
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body cryotherapy (WBC) - 3-min exposure to −120 C, twice a day for 7 days
Study: 36270928
Drug: Lavender oil
Normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender oil inhalation therapy for 5 min (L group)
Study: 36270928
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of foot soak and lavender oil inhalation therapy (FL group)
Study: 36270928
Drug: Foot soak
Normalized name: APIS MELLIFERA VENOM 2.1 g in 7 g / MENTHA PIPERITA LEAF 0.7 g in 7 g / TOCOPHEROL 1.05 g in 7 g TOPICAL LIQUID [HOUKEA Lymphatic Drainage Slimming Foot Soak Beads]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot soak treatment for 20 min (F group)
Study: 32527941
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and targeted therapy
Study: 32527941
Drug: Dose-modifications (increased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-modifications (increased and reduced)
Study: 36160398
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 μg kg−1) and butorphanol (20 μg kg−1)
Study: 36160398
Drug: Midazolam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.05 mg kg−1) and butorphanol (20 μg kg−1)
Study: 35717239
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) using PREVENA PLUS™ Incision Management System
Study: 35906659
Drug: Structured and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured and individualized exercise intervention (9-month multimodal exercise program, 6 months supervised twice a week, followed by 3 months with one supervised and one unsupervised session)
Study: 35247871
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg intravenously; once every 2 weeks for up to 12 months)
Study: 32977820
Drug: Matrix Model
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix Model treatment combined with MPH
Study: 32977820
Drug: Matrix Model
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix Model treatment
Study: 34329624
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus doxycycline (200 mg on day 1, then 100 mg once daily for the following 6 days)
Study: 35441345
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment initiated in 87 patients (73% of relapsed patients)
Study: 35441345
Drug: Local therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local therapy (irradiation or surgical intervention) in 27 patients (23% of relapsed patients)
Study: 33108201
Drug: Anti-GroEL antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-GroEL antibody
Study: 33108201
Drug: Anti-CagA antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CagA antibody
Study: 33108201
Drug: Anti-HP1118/Ggt, Anti-HP0516/HsIU,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HP1118/Ggt, Anti-HP0516/HsIU, Anti-HP0243/NapA, Anti-HP1293/RpoA, Anti-HP0371/FabE, Anti-HP0875/KatA antibodies
Study: 32100498
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment at specific acupuncture points (Fengshi, Futu, Zusanli, Shangjuxu, Fenglong, Xuanzhong, Diji, Sanyinjiao) for 20-30 min, twice a day for 7 days.
Study: 32100498
Drug: Routine rehabilitation
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine rehabilitation treatment (control group).
Study: 32178648
Drug: Pedometer-based walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pedometer-based walking intervention (6-month program with 3 months of pedometers and weekly step count targets)
Study: 32822222
Drug: Microwave ablation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microwave ablation, radiotherapy, and chemotherapy
Study: 32822222
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with pemetrexed disodium or gemcitabine hydrochloride, cisplatin chemotherapy, and conventional radiotherapy
Study: 35543941
Drug: Head acupuncture
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head acupuncture combined with exercise therapy
Study: 34228612
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (an anabolic steroid) in combination with vitamin D
Study: 34228612
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anabolic steroid treatment)
Study: 32100946
Drug: Guideline-directed LVAD
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed LVAD destination therapy (GD-LVAD-DT) using the HeartMate 3 (HM3) continuous flow pump
Study: 34389340
Drug: Chemoradiotherapy (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (2 courses of 5‐fluorouracil 700 mg/m2 on days 1‐4 and cisplatin 70 mg/m2 on day 1 every 4 weeks with concurrent radiation 60 Gy)
Study: 32475278
Drug: Microorganism-directed oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microorganism-directed oral antibiotics for three months
Study: 32056873
Drug: Vortioxetine 10
Normalized name: vortioxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10 mg once daily during the open-label period
Study: 32056873
Drug: Vortioxetine 5
Normalized name: vortioxetine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 5 mg, 10 mg, or 20 mg
Study: 33184726
Drug: 1-month dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy
Study: 36010995
Drug: Tapentadol (TP)
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapentadol (TP) 50 to 500 mg/day
Study: 36010995
Drug: Tapentadol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol plus Duloxetine (DLX) 60 to 120 mg/day
Study: 34627829
Drug: 0.5 μg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg.kg‐1 dexmedetomidine (DEX 0.5 group)
Study: 34627829
Drug: 1 μg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg.kg‐1 dexmedetomidine (DEX 1 group)
Study: 33935153
Drug: Physical therapy-guided
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy-guided movement supplemented with virtual reality
Study: 33935153
Drug: Physical therapy-guided
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy-guided movement alone without virtual reality
Study: 32869592
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of mouse nerve growth factor (mNGF) at various acupoints (0.3-0.5 mL, total 18 µg/2 mL)
Study: 32869592
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of mouse nerve growth factor (mNGF) (18 µg/2 mL)
Study: 32869592
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (Acupoint and Intramuscular)
Study: 32869592
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection of mouse nerve growth factor (mNGF)
Study: 32340650
Drug: Sodium Selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium Selenite (SS) addition (0.3 mg Se/kg DM)
Study: 32340650
Drug: Coated Sodium
Normalized name: psyllium seed coatings,blond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated Sodium Selenite (CSS) addition (0.1, 0.2 and 0.3 mg Se/kg DM)
Study: 32340650
Drug: Medium Coated
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium Coated Sodium Selenite (MCSS) addition (0.2 mg Se/kg DM)
Study: 32340650
Drug: High Coated
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Coated Sodium Selenite (HCSS) addition (0.3 mg Se/kg DM)
Study: 36375565
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal treatment (NSPT) including oral hygiene instructions, scaling and root planing; and 0.05% Chlorhexidine mouthrinse
Study: 36375565
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment including oral hygiene instructions, supragingival removal of plaque and calculus and 0.05% Chlorhexidine mouthrinse
Study: 34085475
Drug: Sham-auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-auricular point therapy
Study: 35671228
Drug: 3% PN
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3% PN in a 40% HP gel for 45 minutes (Group D)
Study: 32449942
Drug: Prazosin 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 16 mg/d, T.I.D.
Study: 32212983
Drug: Fenofibrate 200
Normalized name: fenofibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 200 mg orally once daily
Study: 32212983
Drug: Coenzyme A
Normalized name: Coenzyme A
DrugBank: Coenzyme A (DB01992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme A 400 mg orally once daily
Study: 33839766
Drug: Activity tracker
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity tracker intervention (Polar Loop 2) worn daily for 12 months
Study: 34382947
Drug: AXA1125 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXA1125 24 g
Study: 34382947
Drug: AXA1957 20.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXA1957 20.3 g